Pål Klepstad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pål Klepstad has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
P. C. Borchgrevink
Department of Anesthesia and Medical Imaging and
2 shared publicationsS. Kaasa
Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway
2 shared publicationsBjørn Hval
1 shared publicationM. Skauge
Department of Anesthesia and Medical Imaging and
1 shared publicationPetter Borchgrevink
1 shared publicationSiri Flaat
1 shared publication
Latest Publications
- 1 December 2001
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 23 (9) , 616-619
Long-Term Treatment With Ketamine in a 12-Year-Old Girl With Severe Neuropathic Pain Caused by a Cervical Spinal Tumor
A 12-year-old girl presented with head and neck pain, myoclonic movements, and decreased strength in all extremities caused by a cervical spinal tumor (glioblastoma multiforme). A partial resection of the tumor was performed. Three weeks later, she had superficial pain distributed in all dermatomes below her cervical medullary lesion. Touch (e.g., gentle hugs from relatives) and movements elicited paroxysm of intense pain. The pain was not relieved by increased doses of morphine. A test dose of ketamine (7.5 mg intravenous) provided an abrupt decrease in pain intensity, and continuous infusions of subcutaneous morphine and intravenous ketamine were started. Benzodiazepines were administered to avoid psychotomimetic effects from ketamine and to diminish myoclonic movements. The doses of analgesics and benzodiazepines were increasingly titrated (subcutaneous morphine 163–750 mg/24 hr, intravenous ketamine 36–410 mg/24 hr, subcutaneous midazolam 5–20 mg/24 hr, and intravenous diazepam 11.5–122.5 mg/24 hr) until her death 67 days after start of ketamine. She remained awake until the last day before her death. For the last 29 days of life, the pain treatment regimen was successfully continued in her home (400-km distance from the hospital).In conclusion, this case demonstrates that ketamine treatment may be effective in children with severe neuropathic pain not responsive to other analgesics. This patient also demonstrates the feasibility of long-term ketamine treatment in pediatric oncology and that such treatment can be administered in a home care setting.
- 1 December 2001
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 23 (9) , 616-619
Long-Term Treatment With Ketamine in a 12-Year-Old Girl With Severe Neuropathic Pain Caused by a Cervical Spinal Tumor
A 12-year-old girl presented with head and neck pain, myoclonic movements, and decreased strength in all extremities caused by a cervical spinal tumor (glioblastoma multiforme). A partial resection of the tumor was performed. Three weeks later, she had superficial pain distributed in all dermatomes below her cervical medullary lesion. Touch (e.g., gentle hugs from relatives) and movements elicited paroxysm of intense pain. The pain was not relieved by increased doses of morphine. A test dose of ketamine (7.5 mg intravenous) provided an abrupt decrease in pain intensity, and continuous infusions of subcutaneous morphine and intravenous ketamine were started. Benzodiazepines were administered to avoid psychotomimetic effects from ketamine and to diminish myoclonic movements. The doses of analgesics and benzodiazepines were increasingly titrated (subcutaneous morphine 163–750 mg/24 hr, intravenous ketamine 36–410 mg/24 hr, subcutaneous midazolam 5–20 mg/24 hr, and intravenous diazepam 11.5–122.5 mg/24 hr) until her death 67 days after start of ketamine. She remained awake until the last day before her death. For the last 29 days of life, the pain treatment regimen was successfully continued in her home (400-km distance from the hospital).In conclusion, this case demonstrates that ketamine treatment may be effective in children with severe neuropathic pain not responsive to other analgesics. This patient also demonstrates the feasibility of long-term ketamine treatment in pediatric oncology and that such treatment can be administered in a home care setting.
- 1 July 2000
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 44 (6) , 656-664
Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation
Background: Considerable dose variations and frequent initial side effects have been postulated during start of morphine treatment to patients with pain caused by malignant disease. However, to our knowledge, only one previous study has reported effective doses in morphine naive cancer patients and no prospective evaluation has compared symptoms before with symptoms during morphine titration. Methods: We recruited 40 cancer patients with uncontrolled pain despite receiving codeine or dextropropoxyphen. Baseline data were obtained for two days before start of morphine titration using a fixed scheduled escalation of immediate‐release (IR) morphine. When a stable morphine dose was achieved, IR morphine was replaced with slow‐release (SR) morphine in equivalent doses. Intensity of pain and side effects were assessed daily. The daily consumption of morphine, rescue analgesics and rescue antiemetics were registered. Results: The mean titration time to achieve adequate analgesia was 2.3 days (range: 1–6) using a mean daily morphine dose of 97 mg (range: 60–180). Nausea was unaltered after start with morphine but an increased incidence of vomiting occurred (premorphine period 5%, IR morphine period 29%). Transient sedation delayed dose increment in 9 of the 40 patients but mean sedation scores were unaltered. Constipation scores increased while other side effect scores were unaltered. Eighty‐two percent of the patients were satisfied or very satisfied with the pain treatment during introduction of morphine. Conclusion: In cancer patients with uncontrolled pain on weak opioids, successful titration of morphine is achieved fast, with a three‐fold morphine dose variation and with little increase in side effects.
- 1 July 2000
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 44 (6) , 656-664
Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation
Background: Considerable dose variations and frequent initial side effects have been postulated during start of morphine treatment to patients with pain caused by malignant disease. However, to our knowledge, only one previous study has reported effective doses in morphine naive cancer patients and no prospective evaluation has compared symptoms before with symptoms during morphine titration. Methods: We recruited 40 cancer patients with uncontrolled pain despite receiving codeine or dextropropoxyphen. Baseline data were obtained for two days before start of morphine titration using a fixed scheduled escalation of immediate‐release (IR) morphine. When a stable morphine dose was achieved, IR morphine was replaced with slow‐release (SR) morphine in equivalent doses. Intensity of pain and side effects were assessed daily. The daily consumption of morphine, rescue analgesics and rescue antiemetics were registered. Results: The mean titration time to achieve adequate analgesia was 2.3 days (range: 1–6) using a mean daily morphine dose of 97 mg (range: 60–180). Nausea was unaltered after start with morphine but an increased incidence of vomiting occurred (premorphine period 5%, IR morphine period 29%). Transient sedation delayed dose increment in 9 of the 40 patients but mean sedation scores were unaltered. Constipation scores increased while other side effect scores were unaltered. Eighty‐two percent of the patients were satisfied or very satisfied with the pain treatment during introduction of morphine. Conclusion: In cancer patients with uncontrolled pain on weak opioids, successful titration of morphine is achieved fast, with a three‐fold morphine dose variation and with little increase in side effects.
- 20 January 2000
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 55 (10) , 713-719
Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine
Objective: To investigate the serum concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) and the relationships between serum concentrations and clinical effects associated with start of morphine treatment in cancer patients. Methods: Forty patients with malignant disease and intolerable pain on weak opioids (codeine/dextropropoxyphen) were included. After a wash-out period, titration with immediate-release (IR) morphine was started. When a stable dose was achieved, the morphine treatment was changed to slow-release (SR) morphine in equivalent daily dosages. Clinical data and serum concentrations of morphine, M3G and M6G were obtained at the end of the IR and SR morphine treatment periods. Results: The mean trough serum morphine concentration associated with pain relief was 66 nmol/l. The corresponding mean concentrations of M6G and M3G were 257 nmol/l and 1943 nmol/l, respectively. Morphine serum trough concentrations showed a 33-fold variation. Seventy percent of the variation was predicted in a model including age, daily morphine dose and M6G/morphine ratio as independent variables. No associations were observed between side effects and serum concentrations of morphine and its metabolites. Conclusion: In this study, a mean serum trough morphine concentration of 66 nmol/l was associated with satisfactory pain relief when disease progression required an increase in intensity of pain therapy from step II to step III in the World Health Organization pain ladder. An increased ratio of M6G to morphine serum concentrations predicted lower effective serum morphine concentrations at the time of satisfactory pain relief. This observation supports that M6G contributes to the pain control produced by oral morphine in patients with pain caused by malignant disease.
- 20 January 2000
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 55 (10) , 713-719
Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine
Objective: To investigate the serum concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) and the relationships between serum concentrations and clinical effects associated with start of morphine treatment in cancer patients. Methods: Forty patients with malignant disease and intolerable pain on weak opioids (codeine/dextropropoxyphen) were included. After a wash-out period, titration with immediate-release (IR) morphine was started. When a stable dose was achieved, the morphine treatment was changed to slow-release (SR) morphine in equivalent daily dosages. Clinical data and serum concentrations of morphine, M3G and M6G were obtained at the end of the IR and SR morphine treatment periods. Results: The mean trough serum morphine concentration associated with pain relief was 66 nmol/l. The corresponding mean concentrations of M6G and M3G were 257 nmol/l and 1943 nmol/l, respectively. Morphine serum trough concentrations showed a 33-fold variation. Seventy percent of the variation was predicted in a model including age, daily morphine dose and M6G/morphine ratio as independent variables. No associations were observed between side effects and serum concentrations of morphine and its metabolites. Conclusion: In this study, a mean serum trough morphine concentration of 66 nmol/l was associated with satisfactory pain relief when disease progression required an increase in intensity of pain therapy from step II to step III in the World Health Organization pain ladder. An increased ratio of M6G to morphine serum concentrations predicted lower effective serum morphine concentrations at the time of satisfactory pain relief. This observation supports that M6G contributes to the pain control produced by oral morphine in patients with pain caused by malignant disease.